V1RA8 Inhibitors
V1RA8 inhibitors represent a specialized class of chemical compounds that are designed to interact with the V1RA8 protein. This class is characterized by a diverse range of molecular structures, each carefully engineered to exhibit specific interactions with V1RA8. The compounds often feature intricate scaffolds that may include cyclic structures, heterocycles, and a variety of functional groups tailored for high affinity and selectivity. Common structural motifs in V1RA8 inhibitors include aromatic rings, alkyl chains, and polar groups, which together enhance their ability to bind to the target protein. The diversity in structure allows these inhibitors to modulate the activity of V1RA8 through various mechanisms, often by fitting into a distinct binding pocket or influencing the protein's conformational changes.
The development of V1RA8 inhibitors involves sophisticated chemical synthesis techniques and extensive screening processes. Chemists utilize a combination of organic synthesis strategies, such as multi-step synthesis, combinatorial chemistry, and structure-guided design, to create and optimize these inhibitors. Advanced methods like molecular docking and quantitative structure-activity relationship (QSAR) modeling are employed to predict and enhance the binding interactions between the inhibitors and V1RA8. Each V1RA8 inhibitor is carefully evaluated for its binding affinity, specificity, and potential to modulate the protein's function. The iterative design and refinement process ensures that these inhibitors achieve high efficacy in interacting with V1RA8, making them valuable tools for studying the protein's role and behavior in various biochemical contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D inhibits the expression of vomeronasal 1 receptor, A8 by intercalating into DNA, thereby preventing transcription initiation and elongation, ultimately blocking mRNA synthesis and reducing protein expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits the expression of vomeronasal 1 receptor, A8 by binding to RNA polymerase II, blocking transcriptional elongation, and leading to decreased mRNA levels, consequently reducing the synthesis of the receptor protein. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits the expression of vomeronasal 1 receptor, A8 by binding to the 60S ribosomal subunit, preventing peptide bond formation during translation, resulting in decreased synthesis of the receptor protein. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Rifampicin inhibits the expression of vomeronasal 1 receptor, A8 by binding to bacterial RNA polymerase, blocking transcription initiation, and indirectly reducing mRNA levels, ultimately leading to decreased receptor protein synthesis. | ||||||
Thiolutin | 87-11-6 | sc-200387 sc-200387A | 1 mg 5 mg | $101.00 $406.00 | 1 | |
Thiolutin inhibits the expression of vomeronasal 1 receptor, A8 by binding to RNA polymerase and preventing transcriptional elongation, resulting in decreased mRNA synthesis and ultimately reduced protein expression. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin inhibits the expression of vomeronasal 1 receptor, A8 by being incorporated into mRNA during transcription, causing premature termination of transcription and reduced mRNA levels, ultimately leading to decreased protein synthesis. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $42.00 $214.00 $832.00 $66.00 | 394 | |
Puromycin inhibits the expression of vomeronasal 1 receptor, A8 by incorporating into growing polypeptide chains during translation, causing premature termination of protein synthesis and synthesis of truncated proteins. | ||||||
Siomycin A | 12656-09-6 | sc-202339 sc-202339-CW sc-202339A sc-202339B | 500 µg 500 µg 2.5 mg 25 mg | $450.00 $500.00 $1350.00 $10404.00 | 4 | |
Siomycin A inhibits the expression of vomeronasal 1 receptor, A8 by binding to RNA polymerase and preventing the formation of the transcription complex, leading to transcriptional arrest and reduced mRNA synthesis, ultimately decreasing receptor protein levels. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $52.00 $125.00 $182.00 | 11 | |
Homoharringtonine inhibits the expression of vomeronasal 1 receptor, A8 by binding to the ribosome and inhibiting protein synthesis, resulting in decreased levels of the receptor protein. | ||||||